Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation.

Lung cancer (Amsterdam, Netherlands) - 1 Aug 2012

Lee June Koo, Kim Tae Min, Koh Youngil, Lee Se-Hoon, Kim Dong-Wan, Jeon Yoon-Kyung, Chung Doo Hyun, Yang Seok-Chul, Kim Young Tae, Kim Young-Whan, Heo Dae Seog, Bang Yung-Jue

Abstract excerpt

Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations in non-small cell lung cancer (NSCLC) are mutually exclusive. However, several exceptional cases harboring both genetic alterations have been reported. In this study, a total of 444 patients with lung adenocarcinoma were examined for their EGFR and ALK status at Seoul National University Hospital between July...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Receptor Protein-Tyrosine Kinases

Share to Translocation, Genetic

Source

Identifiers

PMID: 22622260
DOI: 10.1016/j.lungcan.2012.04.012

Genes

ALK
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation.PMID 22622260Read ↗

[Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer].Semantic proximity Read ↗

ALK alterations and inhibition in lung cancer.Semantic proximity Read ↗

Clinicopathological features and diagnostic methods of ALK fusion‑positive non‑small cell lung cancer in Korea.Semantic proximity Read ↗

Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.Semantic proximity Read ↗

Concurrent driver mutations/rearrangements in non-small-cell lung cancer.Semantic proximity Read ↗

Rare Complex Mutational Profile in an ALK Inhibitor-resistant Non-small Cell Lung Cancer.Semantic proximity Read ↗

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.Semantic proximity Read ↗

The Exploratory Research of NSCLC with Concomitant EGFR Mutations and ALK RearrangementsSemantic proximity Read ↗

Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.Semantic proximity Read ↗

Protein kinase inhibitors to treat non-small-cell lung cancerSemantic proximity Read ↗

Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.Semantic proximity Read ↗

Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAFSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.